title: Multidrug-resistant TB in Eastern region of the EU: is the shorter regimen an exception or a rule?
abstract: WHO recently recommended the use of a shorter multidrug-resistant TB (MDR-TB) regimen under programmatic conditions. We assessed eligibility for this regimen in a cohort of 737 adult patients with MDR-TB from Latvia, Lithuania, Estonia and Bucharest city recruited in 2007 and 2009. Only 4.2% of the patients were eligible for this regimen. Ethambutol (64%), pyrazinamide resistance (58%) and previous exposure to second-line TB drugs were major reasons for non-eligibility. High-level resistance to isoniazid is expected due to widespread prevalence ofkatGmutations. In Eastern Europe, the use of the shorter regimen might be an exception rather than a rule.
authors.affiliation: Blizard Institute, Queen Mary, University of London, London, UK.|Department of Infectious Diseases, Imperial College London, London, UK.|Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
authors.forename: Yanina
authors.initials: Y
authors.lastname: Balabanova
authors.affiliation: Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
authors.forename: Lena
authors.initials: L
authors.lastname: Fiebig
authors.affiliation: N.V. Postnikov Samara Region Clinical Tuberculosis Dispensary, Samara, Russia.
authors.forename: Olga
authors.initials: O
authors.lastname: Ignatyeva
authors.affiliation: Department of Mycobacteriology, State Agency "Infectology Center of Latvia," Clinic for Tuberculosis and Lung Diseases, "Upeslejas" Stopinunovads, Riga, Latvia.
authors.forename: Vija
authors.initials: V
authors.lastname: Riekstina
authors.affiliation: United Laboratory, Department of Mycobacteriology, Tartu University Hospital, Tartu, Estonia.
authors.forename: Manfred
authors.initials: M
authors.lastname: Danilovits
authors.affiliation: United Laboratory, Department of Mycobacteriology, Tartu University Hospital, Tartu, Estonia.
authors.forename: Kaadri
authors.initials: K
authors.lastname: Jaama
authors.affiliation: National Tuberculosis and Infectious Diseases University Hospital, Vilnius, Lithuania.
authors.forename: Edita
authors.initials: E
authors.lastname: Davidaviciene
authors.affiliation: National Tuberculosis and Infectious Diseases University Hospital, Vilnius, Lithuania.
authors.forename: Birute
authors.initials: B
authors.lastname: Radiulyte
authors.affiliation: Marius Nasta Institute of Pneumology, Bucharest, Romania.
authors.forename: Christina Marcela
authors.initials: CM
authors.lastname: Popa
authors.affiliation: Blizard Institute, Queen Mary, University of London, London, UK.|Department of Infectious Diseases, Imperial College London, London, UK.|National Mycobacterium Reference Service South, Public Health England, London, UK.
authors.forename: Vladyslav
authors.initials: V
authors.lastname: Nikolayevskyy
authors.affiliation: Blizard Institute, Queen Mary, University of London, London, UK.|Department of Infectious Diseases, Imperial College London, London, UK.
authors.forename: Francis
authors.initials: F
authors.lastname: Drobniewski
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D005061:Europe, Eastern; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents
keywords: Tuberculosis